ATE484281T1 - Heterocyclische verbindungen die als beta- lactamasehemmer aktiv sind - Google Patents

Heterocyclische verbindungen die als beta- lactamasehemmer aktiv sind

Info

Publication number
ATE484281T1
ATE484281T1 AT03709903T AT03709903T ATE484281T1 AT E484281 T1 ATE484281 T1 AT E484281T1 AT 03709903 T AT03709903 T AT 03709903T AT 03709903 T AT03709903 T AT 03709903T AT E484281 T1 ATE484281 T1 AT E484281T1
Authority
AT
Austria
Prior art keywords
beta
active
heterocyclic compounds
lactamase inhibitors
lactamase
Prior art date
Application number
AT03709903T
Other languages
English (en)
Inventor
Jozsef Aszodi
Claude Fromentin
Maxime Lampilas
David Rowlands
Original Assignee
Novexel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27619669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE484281(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novexel filed Critical Novexel
Application granted granted Critical
Publication of ATE484281T1 publication Critical patent/ATE484281T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03709903T 2002-01-28 2003-01-27 Heterocyclische verbindungen die als beta- lactamasehemmer aktiv sind ATE484281T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0200951A FR2835186B1 (fr) 2002-01-28 2002-01-28 Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
PCT/FR2003/000243 WO2003063864A2 (fr) 2002-01-28 2003-01-27 Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases

Publications (1)

Publication Number Publication Date
ATE484281T1 true ATE484281T1 (de) 2010-10-15

Family

ID=27619669

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03709903T ATE484281T1 (de) 2002-01-28 2003-01-27 Heterocyclische verbindungen die als beta- lactamasehemmer aktiv sind

Country Status (44)

Country Link
US (4) US7612087B2 (de)
EP (2) EP1480644B1 (de)
JP (1) JP4472346B2 (de)
KR (1) KR100979079B1 (de)
CN (3) CN100482225C (de)
AR (2) AR038234A1 (de)
AT (1) ATE484281T1 (de)
AU (1) AU2003214335B2 (de)
BE (1) BE2016C069I2 (de)
BR (1) BRPI0307267B8 (de)
CA (1) CA2474043C (de)
CL (1) CL2011000009A1 (de)
CO (1) CO5601014A2 (de)
CR (2) CR7387A (de)
CY (3) CY1111061T1 (de)
DE (1) DE60334527D1 (de)
DK (2) DK2279737T3 (de)
EA (1) EA007220B1 (de)
EC (1) ECSP045193A (de)
ES (2) ES2401855T3 (de)
FR (2) FR2835186B1 (de)
HR (1) HRP20040686B1 (de)
HU (1) HUS1600055I1 (de)
IL (1) IL163167A (de)
JO (1) JO2646B1 (de)
LT (1) LTC1480644I2 (de)
MA (1) MA26351A1 (de)
MX (1) MXPA04006621A (de)
MY (1) MY140638A (de)
NL (1) NL300847I2 (de)
NO (3) NO335195B1 (de)
NZ (1) NZ533936A (de)
OA (1) OA12761A (de)
PE (1) PE20030969A1 (de)
PL (1) PL220725B1 (de)
PT (2) PT1480644E (de)
RS (1) RS52137B (de)
SI (2) SI2279737T1 (de)
TN (1) TNSN04137A1 (de)
TW (1) TWI293071B (de)
UA (1) UA80271C2 (de)
UY (1) UY27626A1 (de)
WO (1) WO2003063864A2 (de)
ZA (1) ZA200405607B (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
WO2007063552A1 (en) * 2005-12-02 2007-06-07 Lupin Limited Stable taste masked formulations of cephalosporins
SI1965798T1 (sl) 2005-12-07 2012-01-31 Basilea Pharmaceutica Ag Uporabni monobaktamski antibiotiki
EP2040698A4 (de) * 2006-07-14 2011-08-10 Shionogi & Co Oximverbindungen und ihre verwendung
EP2078027A1 (de) * 2006-10-23 2009-07-15 Irm Llc Cathepsin-proteasehemmer
ES2422603T3 (es) * 2007-05-31 2013-09-12 Shionogi & Co Compuestos oxiimino y el uso de estos
FR2921060B1 (fr) * 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
SI2231667T1 (sl) * 2008-01-18 2013-12-31 Merck Sharp & Dohme Corp. Beta laktamazni inhibitorji
US20110046101A1 (en) * 2008-03-17 2011-02-24 Dmitrienko Gary I Bate-lactamase inhibitors
FR2930553B1 (fr) * 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
JP5501983B2 (ja) * 2008-06-11 2014-05-28 塩野義製薬株式会社 オキシカルバモイル化合物およびその使用
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr) * 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
AU2014244235B2 (en) * 2009-10-09 2016-04-21 Pfizer Ireland Pharmaceuticals Polymorphic and pseudopolymorphic forms of a pharmaceutical compound
BR112013003045B1 (pt) 2010-08-10 2021-08-31 Rempex Pharmaceuticals, Inc. Composto e respectivo uso, composição farmacêutica, recipiente estéril e método para preparar composição farmacêutica para administração
CN104892490B (zh) * 2010-12-22 2017-07-21 明治制果药业株式会社 用于制备光学活性二氮杂环辛烷衍生物的中间体化合物的化合物
US8772490B2 (en) * 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
WO2012172368A1 (en) * 2011-06-17 2012-12-20 Astrazeneca Ab Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
KR101512738B1 (ko) * 2011-08-27 2015-04-17 욱크하르트 리미티드 1,6-디아자-비시클로[3,2,1]옥탄-7-온 유도체 및 세균 감염 치료에서의 그 유도체의 용도
US9102683B2 (en) 2011-08-29 2015-08-11 University Of Utah Research Foundation Heterocyclic compounds
US20130053565A1 (en) * 2011-08-29 2013-02-28 University Of Utah Research Foundation Substituted 3-piperidone compounds
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
EP3052497B1 (de) * 2011-09-13 2017-06-28 Wockhardt Limited Stickstoffhaltige verbindungen und ihre verwendung
US8969567B2 (en) * 2011-09-13 2015-03-03 Wockhardt Ltd. Nitrogen containing compounds and their use
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
MX2014011827A (es) 2012-03-30 2015-02-20 Cubist Pharm Inc Inhibidores de 1,3,4 - oxadiazol y 1,3,4 - tiadiazol b-lactamasa.
SG11201406120SA (en) 2012-03-30 2014-10-30 Cubist Pharm Inc ISOXAZOLE β-LACTAMASE INHIBITORS
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
UA117734C2 (uk) 2012-05-30 2018-09-25 Мейдзі Сейка Фарма Ко., Лтд. НОВИЙ ІНГІБІТОР β-ЛАКТАМАЗИ І СПОСІБ ЙОГО ОДЕРЖАННЯ
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
BR112015003592B1 (pt) * 2012-08-25 2020-04-14 Wockhardt Ltd derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
UA111925C2 (uk) * 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
MX2015008627A (es) 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2894891A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9120795B2 (en) 2013-03-14 2015-09-01 Cubist Pharmaceuticals, Inc. Crystalline form of a β-lactamase inhibitor
MY176278A (en) 2013-09-24 2020-07-27 Meiji Seika Pharma Co Ltd Process for producing diazabicyclooctane derivative and intermediate thereof
WO2015051101A1 (en) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
NZ757221A (en) 2013-10-08 2021-12-24 Meiji Seika Pharma Co Ltd Crystalline forms of diazabicyclooctane derivative and production process thereof
EP3107539A1 (de) * 2014-02-20 2016-12-28 Wockhardt Limited Pharmazeutische zusammensetzungen mit antibakteriellen wirkstoffen
CN103896936A (zh) * 2014-03-20 2014-07-02 西安交通大学 (5s,6r)氯唑西林青霉噻唑酸盐及其制备方法和应用
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
RS59488B1 (sr) 2014-05-05 2019-12-31 Rempex Pharmaceuticals Inc Sinteza boronatnih soli i njihove upotrebe
KR20170007448A (ko) 2014-05-19 2017-01-18 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
CN104059083B (zh) * 2014-05-27 2017-01-04 浙江工业大学 一种手性二环己内酰胺类化合物的不对称合成方法
EP3164406B1 (de) 2014-07-01 2024-12-25 Qpex Biopharma, Inc. Borsäurederivate und therapeutische verwendungen davon
SI3221313T1 (sl) 2014-11-17 2019-04-30 Entasis Therapeutics Limited Kombinacijska terapija za zdravljenje okužb z rezistentnimi bakterijami
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
BR112017010445B8 (pt) 2014-12-05 2024-02-27 Meiji Seika Pharma Co Ltd Processo de produção de cristais de derivado de diazabiciclo-octano e preparação liofilizada estável
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
MX2017014080A (es) * 2015-05-07 2018-07-06 Mutabilis Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
EP3281942A4 (de) * 2015-09-16 2018-08-15 Xuanzhu Pharma Co., Ltd. B-lactamase-hemmer und verwendung davon
CN108137567A (zh) 2015-10-02 2018-06-08 乐高化学生物科学股份有限公司 用于抑制β-内酰胺酶的组合物和方法
WO2017156458A1 (en) 2016-03-11 2017-09-14 University Of South Florida Beta-lactamase inhibitors, formulations, and uses thereof
ES2734773T3 (es) 2016-05-27 2019-12-11 Valoralia I Mas D Sl Compuestos de dihidrooxadiazina para tratar infecciones y cáncer
US10294249B2 (en) 2016-06-30 2019-05-21 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CN106279163A (zh) * 2016-08-12 2017-01-04 上海龙翔生物医药开发有限公司 一种合成阿维巴坦及其中间体光学异构体的方法
CN107789355B (zh) * 2016-09-07 2022-04-12 湘北威尔曼制药股份有限公司 含有哌拉西林的复方药物组合物及其应用
SMT202200397T1 (it) 2016-09-16 2022-11-18 Entasis Therapeutics Ltd Composti inibitori di beta-lattamasi
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法
BR112019015834A2 (pt) 2017-02-06 2020-03-31 Mutabilis Compostos, composição farmacêutica, kit e uso de um composto ou uma composição
CN110709081B (zh) 2017-05-08 2023-09-22 恩塔西斯治疗公司 用于治疗细菌感染的化合物及方法
WO2018234962A1 (en) 2017-06-20 2018-12-27 Wockhardt Limited Process for o-sulfonation of 1,6-diazabicyclo[3.2.1]octane compounds
US11286270B2 (en) 2017-10-11 2022-03-29 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
CN109678856B (zh) * 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
TW201925201A (zh) * 2017-11-10 2019-07-01 日商鹽野義製藥股份有限公司 二氮雜二環辛烷衍生物
EP3781576B1 (de) 2018-04-20 2024-06-12 Qpex Biopharma, Inc. Borsäurederivate und therapeutische verwendungen davon
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3833665B1 (de) 2018-08-09 2023-07-19 Antabio SAS Diazabicyclooctanones als inhibitoren von serin-beta-lactamasen
CN109942579B (zh) * 2019-04-18 2021-06-22 成都千禧莱医药科技有限公司 β-内酰胺酶抑制剂含脲双环化合物及其制备方法和应用
EP4146650A4 (de) * 2020-09-01 2024-01-17 Ningxia Academy of Agriculture and Forestry Sciences Beta-lactamase-hemmer und ihre herstellung
WO2022047790A1 (en) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors
EP4146651A4 (de) 2021-05-07 2024-06-05 Ningxia Academy of Agriculture and Forestry Sciences Sulfonylamidinsubstituierte verbindungen und ihre verwendung als beta-lactamase-hemmer
WO2023060369A1 (en) * 2021-10-11 2023-04-20 Ningxia Academy Of Agriculture And Forestry Sciences Novel carbimidate substituted bicyclic compounds and their use as beta-lactamase inhibitors
KR20240041506A (ko) 2022-09-23 2024-04-01 주식회사 경보제약 아비박탐 나트륨 염의 안정한 일수화물 형태 및 그의 제조 방법
CN116375706B (zh) * 2023-02-22 2025-02-14 时森海(杭州)医药科技有限公司 阿维巴坦钠关键中间体及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260057A3 (de) 1986-09-02 1989-02-01 The University Of Melbourne 2-Oxo-4-Karboxypyrimidine
KR0167346B1 (ko) 1989-06-09 1999-01-15 로버트 에이. 아미테이지 중추신경계 활성을 갖는 헤테로사이클릭 아민
FR2676230B1 (fr) 1991-05-07 1993-08-27 Centre Nat Rech Scient Nouveaux derives de pyrrolo [1,4]-benzodiazepines, leur procede de preparation et medicaments les contenant.
JPH05339263A (ja) 1992-06-08 1993-12-21 Wakunaga Pharmaceut Co Ltd ジヒドロピリジン誘導体
EP0724587B8 (de) 1993-09-29 2003-01-29 Nabi Nukleoside und nukleotide mit vergrösserten ringen
CZ282567B6 (cs) * 1993-12-29 1997-08-13 Pfizer Inc. Diazabicyklické sloučeniny a farmaceutické prostředky na jejich bázi
EP0702004A2 (de) * 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative
GB9505538D0 (en) 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
SE9504618D0 (sv) 1995-12-22 1995-12-22 Astra Ab New Compounds
HUP9900973A3 (en) * 1996-01-03 2000-04-28 Smithkline Beecham Plc Carbamoyloxy derivatives of mutiline with antibacterial activity, pharmaceutical compns. contg. them and process for preparing the said compds.
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
HUP0001741A3 (en) * 1996-08-02 2000-11-28 Smithkline Beecham Plc Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use, process for preparing them, pharmaceuticals contg. them and their use
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
UY25225A1 (es) * 1997-10-29 2000-12-29 Smithkline Beecham Plc Derivados de pleuromutilina utiles como agentes antimicrobianos
AU5265599A (en) 1998-04-08 1999-11-01 Takeda Chemical Industries Ltd. Amine compounds, their production and their use as somatostatin receptor antagonists or agonists
AU4698399A (en) 1998-06-30 2000-01-17 Du Pont Pharmaceuticals Company 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
JP2002533335A (ja) 1998-12-18 2002-10-08 シェーリング コーポレイション ファルネシルタンパク質トランスフェラーゼインヒビター
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
CA2386517A1 (en) 1999-10-07 2001-04-12 Takeda Chemical Industries, Ltd. Amine derivatives
AU2001246893A1 (en) 2000-04-18 2001-10-30 Sumitomo Pharmaceuticals Company, Limited Tricyclic quinazolinediones
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
DE60220057T2 (de) 2001-02-22 2008-01-10 School Of Pharmacy, University Of London Indoline und Tetrahydrochinoline als Prodrugs zur Tumorbehandlung
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors

Also Published As

Publication number Publication date
CR20120356A (es) 2012-10-05
EP1480644A2 (de) 2004-12-01
CN1994301A (zh) 2007-07-11
CL2011000009A1 (es) 2011-03-25
MY140638A (en) 2010-01-15
DE60334527D1 (de) 2010-11-25
FR2835186B1 (fr) 2006-10-20
CY1114417T1 (el) 2016-08-31
PL220725B1 (pl) 2015-12-31
CY2016042I1 (el) 2017-03-15
IL163167A (en) 2010-04-15
MA26351A1 (fr) 2004-10-01
NO20043587L (no) 2004-08-27
BE2016C069I2 (de) 2022-05-17
MXPA04006621A (es) 2004-10-04
LTC1480644I2 (lt) 2018-09-10
CN1655781A (zh) 2005-08-17
EP2279737B1 (de) 2012-10-31
WO2003063864A2 (fr) 2003-08-07
ES2401855T3 (es) 2013-04-25
UA80271C2 (uk) 2007-09-10
BRPI0307267B8 (pt) 2021-05-25
HK1077205A1 (zh) 2006-02-10
PE20030969A1 (es) 2003-12-12
TW200303305A (en) 2003-09-01
US20110245254A1 (en) 2011-10-06
OA12761A (fr) 2006-07-04
EA007220B1 (ru) 2006-08-25
US7612087B2 (en) 2009-11-03
NO335195B1 (no) 2014-10-20
EP2279737A1 (de) 2011-02-02
PL371601A1 (pl) 2005-06-27
NO2025027I1 (no) 2025-06-13
NZ533936A (en) 2007-05-31
CA2474043C (fr) 2011-08-02
CN101406471A (zh) 2009-04-15
AU2003214335B2 (en) 2007-04-05
ZA200405607B (en) 2005-09-28
LTPA2016037I1 (lt) 2017-01-10
YU65804A (sh) 2006-08-17
WO2003063864A3 (fr) 2004-03-11
KR20040081473A (ko) 2004-09-21
UY27626A1 (es) 2003-08-29
HUS1600055I1 (hu) 2017-01-30
TWI293071B (en) 2008-02-01
CY1111061T1 (el) 2015-06-11
EP1480644B1 (de) 2010-10-13
BRPI0307267B1 (pt) 2016-02-10
HRP20040686A2 (en) 2004-12-31
ECSP045193A (es) 2004-08-27
RS52137B (sr) 2012-08-31
SI2279737T1 (sl) 2013-07-31
CA2474043A1 (fr) 2003-08-07
US20090215747A1 (en) 2009-08-27
FR2835186A1 (fr) 2003-08-01
NL300847I2 (de) 2017-01-03
BR0307267A (pt) 2004-12-07
KR100979079B1 (ko) 2010-08-31
FR16C1019I1 (fr) 2017-02-03
PT2279737E (pt) 2013-02-01
DK1480644T3 (da) 2011-01-24
US20100048528A1 (en) 2010-02-25
PT1480644E (pt) 2011-01-17
NO2016024I1 (no) 2016-12-15
DK2279737T3 (da) 2013-02-11
EA200400981A1 (ru) 2005-02-24
SI1480644T1 (sl) 2011-03-31
JP2005523897A (ja) 2005-08-11
AR100790A2 (es) 2016-11-02
FR16C1019I2 (fr) 2017-12-29
CY2016042I2 (el) 2017-03-15
US20050020572A1 (en) 2005-01-27
HK1105864A1 (zh) 2008-02-29
NO2016024I2 (no) 2016-12-15
ES2356813T3 (es) 2011-04-13
JP4472346B2 (ja) 2010-06-02
CR7387A (es) 2010-10-25
JO2646B1 (en) 2012-06-17
TNSN04137A1 (fr) 2007-03-12
CN100563653C (zh) 2009-12-02
CO5601014A2 (es) 2006-01-31
AR038234A1 (es) 2005-01-05
CN100482225C (zh) 2009-04-29
HRP20040686B1 (hr) 2013-02-28

Similar Documents

Publication Publication Date Title
ATE484281T1 (de) Heterocyclische verbindungen die als beta- lactamasehemmer aktiv sind
ATE401328T1 (de) Verbrückte n-arylsulfonylpiperidine als gamma- sekretaseinhibitoren
ATE443706T1 (de) Pyrrolotriazinverbindungen als kinaseinhibitoren
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
DK1448523T3 (da) Heterocycliske forbindelser samt metoder til anvendelse deraf
DK1558585T3 (da) Neurologisk aktive forbindelser
IS8483A (is) Heterósýklísk virk efni gegn mígreni
ATE461191T1 (de) N-substituierte 2-oxodihydropyridinderivate als npy antagonisten
ATE404537T1 (de) Heterocyclische verbindungen mit hiv-integrase- hemmender wirkung
DE602004025258D1 (de) Aminotriazol-verbindungen als proteinkinase-hemmer
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE402934T1 (de) Malonamidderivate als gamma-secretaseinhibitoren
DE60320933D1 (de) Rho-kinase inhibitoren
DK1603570T3 (da) Aminoheteroarylforbindelser som proteinkinaseinhibitorer
DE602004028827D1 (de) Pyrrolodihydroisochinoline als pde10- inhibitoren
DE60324208D1 (de) Biarylsulfonamide als mmp-inhibitoren
ATE402700T1 (de) Glycinamid-derivate als raf-kinase-hemmer
ATE538787T1 (de) Benzimidazol-derivative als raf-kinase-hemmer
ATE461926T1 (de) Substituierte n-arylsulfonylheterocyclische amine als gamma-sekretase-hemmer
ATE425169T1 (de) Heterotricyclyl-6-alkylidenpeneme als beta- lactamaseinhibitoren
NO20052655D0 (no) Sammensmeltede heterocykliske forbindelser
EP1478356A4 (de) Therapeutische verbindungen
DE60328233D1 (de) Sulfamatbenzothiophenderivate als steroidsulfataseinhibitoren
ATE414063T1 (de) N-ä(ä4-substituierten piperazin-1- ylüsulfonylmethyl) alkylü -n-hydroxyformamide verbindungen als metalloproteinase inhibitoren
NO20053726D0 (no) Forbindelser med prolyloligopeptidase-hemmende aktivitet

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1480644

Country of ref document: EP